Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Hansa Biopharma AB's current 3-Year Share Buyback Ratio was -23.90%.
The historical rank and industry rank for Hansa Biopharma AB's 3-Year Share Buyback Ratio or its related term are showing as below:
CHIX:HNSAs'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -42.1 Med: -11.5 Max: -3.6
Current: -23.9
During the past 13 years, Hansa Biopharma AB's highest 3-Year Share Buyback Ratio was -3.60%. The lowest was -42.10%. And the median was -11.50%.
CHIX:HNSAs's 3-Year Share Buyback Ratio is ranked worse than 68.01% of 1188
companies
in the Biotechnology industry
Industry Median: -11.75
vs CHIX:HNSAs: -23.90
Hansa Biopharma AB (CHIX:HNSAs) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Hansa Biopharma AB 3-Year Share Buyback Ratio Related Terms
CHIX:HNSAS vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's 3-Year Share Buyback Ratio falls into.
Hansa Biopharma AB 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -23.90 mean?
Hansa Biopharma AB (CHIX:HNSAS) has a 3-Year Share Buyback Ratio of -23.90 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Hansa Biopharma AB and its competitors. According to the industry distribution chart, Hansa Biopharma AB ranks #808 out of 1188 companies in the Biotechnology industry, placing it in the top 68%.
Is Hansa Biopharma AB's 3-Year Share Buyback Ratio too high?
Hansa Biopharma AB's current 3-Year Share Buyback Ratio is -23.90. Based on the distribution chart, Hansa Biopharma AB ranks #808 out of 1188 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hansa Biopharma AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #808 out of 1188 companies for 3-Year Share Buyback Ratio. This places Hansa Biopharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current 3-Year Share Buyback Ratio is -23.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current 3-Year Share Buyback Ratio of -23.90. The stock's GF Value™ is kr12.25, compared to a current price of kr25.64 — trading 109.3% above its estimated fair value. The current 3-Year Share Buyback Ratio is -23.90. Hansa Biopharma AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current 3-Year Share Buyback Ratio is -23.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr25.64 is trading 109.3% above its estimated GF Value™ of kr12.25.
Key valuation signals for CHIX:HNSAS:
3-Year Share Buyback Ratio: -23.90
GF Value™: kr12.25 vs. price of kr25.64 (109.3% above fair value)
No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
39GF Score
Get the complete analysis for CHIX:HNSAS
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HNSAS has been successfully added to your 
